This site is targeted at medical and radiology professionals, contains user contributed content and material that may be confusing to a lay audience. Use of this site implies acceptance of our Terms of Use.

Alpha-1-antitrypsin deficiency

Dr Henry Knipe and Radswiki et al.

Alpha-1-antitrypsin deficiency is a hereditary metabolic disorder. It is the most common metabolic liver disease in children and results in the unopposed action of neutrophil elastase and subsequent severe basal emphysema and respiratory symptoms.

Clinical presentation

The classic presentation of the disease is with dyspnoea in the 4th to 5th decades of life. Two-thirds of individuals show clinical features but most carriers are asymptomatic.


Alpha-1 antitrypsin (AAT) is a protein that prevents enzymes such as elastase from degrading normal host tissue. Over 90% of the alpha-1-antitrypsin protein is produced in hepatocytes by codominant gene expression on chromosome 14. The alpha-1-antitrypsin protein inhibits neutrophil elastase. In patients with severe deficiency, the neutrophil elastase acts unopposed resulting in damage to the lower respiratory tract. This damage is predominantly basal because of the gravitational distribution of pulmonary blood flow. 


Radiographic features

Thoracic manifestations
Abdominal manifestations

Hepatic manifestations of this disease are those of cirrhosis with the concomitant increased risk of hepatocellular carcinoma

Treatment and prognosis

Emphysema and cirrhosis are usually considered the most common causes of death 8.

Survival is substantially worse in smokers, who have a  -20 year decrease in longevity relative to non-smokers. According to one study, the overall median survival time was ~ 55 years 7.

AAT replacement therapy, most often by weekly intravenous infusions of AAT purified from human plasma, has been used in some situations to partially correct the biochemical defect 14-15.  

While randomized, placebo-controlled clinical trials have confirmed a reduction in the decline in lung density in patients receiving augmentation therapy 14. It's efficacy in reducing mortality however is uncertain 16. Other management strategies include avoidance of smoking and other risk factors for cirrhosis.

Differential diagnosis

The differential will depend upon the the organ involved

Updating… Please wait.


Error Unable to process the form. Check for errors and try again.

Alert_accept Thank you for updating your details.